The high affinity of the LNA™-enhanced microRNA inhibitors makes them highly effective at physiological temperatures and when used in low concentrations, thereby minimizing potential secondary effects not related to the antisense activity of the microRNA inhibitor. In addition, LNA™ incorporation enhances serum and nuclease stability.
The LNA™ technology has been successfully applied in vivo, combining low concentrations of the microRNA inhibitor with high serum stability and low toxicity. Effective inhibition of microRNAs has been observed with concentrations of in vivo LNA™ microRNA Inhibitors as low as 10 mg/kg (ED50) bodyweight.
To learn more, please see the scientific publications listed in the right-hand menu.
Stefanie Dimmeler, Professor and group leader, and Reinier Boon, Post Doctoral researcher, work in the Institute for Cardiovascular Regeneration at the Goethe University Frankfurt, Germany. Here they study the basic mechanisms underlying cardiovascular disease and vessel growth with the aim to develop new therapies to improve treatment of cardiovascular diseases. Read full story...
"LNA microRNA antisense inhibitors are efficient and specific with long lasting effects"
Dr. Annick Harel-Bellan (AHB) is Directeur de Recherche at the Institut Andre Lwoff in Paris. She heads a group working on epigenetics and cancer (Laboratoire Epigenetique et Cancer). Dr. Anna Polesskaya (AP) is a senior scientist and longstanding member of this group Read full story...